跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,794 条关于
“Kv3.1/3.2”
全部
1,794
临床试验
950
药物
383
机构
0
资讯
461
去年
Boehringer Ingelheim Expands Schizophrenia Pipeline with Sosei Heptares and Autifony Collaborations
2个月前
Neuphoria Confirms Merger Talks with Scancell as UK Biotech Eyes Nasdaq Listing
10个月前
Neuphoria Therapeutics Receives $5.20 Per Share Acquisition Offer from Lynx1 Master Fund Following Phase III Trial Failure
去年
Neuphoria Therapeutics Completes Phase 3 Enrollment for BNC-210 Social Anxiety Disorder Treatment
去年
Neuphoria Advances Dual Clinical Programs with Merck Partnership Milestone and Phase 3 SAD Trial Progress
去年
FDA Grant Supports Research into Histomonosis Transmission in Turkeys
9天前
Alteogen licenses ALT-B4 to Novartis in deal worth up to $3.2 billion
去年
Moderna Reports $3.2 Billion in 2024 Revenue, Submits Three mRNA Products for Regulatory Approval
去年
Elevidys Fails to Meet Primary Endpoint in Phase 3 EMBARK Trial for Duchenne Muscular Dystrophy
2个月前
Alteogen Signs Up to $3.2 Billion Option and Licensing Deal with Novartis for Subcutaneous Formulations
第 1 页,共 47 页
上一页
下一页